Urseptiya (Capsules) Instructions for Use
Marketing Authorization Holder
Velpharm, LLC (Russia)
ATC Code
J01MB04 (Pipedemic acid)
Active Substance
Pipemidic acid (Rec.INN registered by WHO)
Dosage Form
| Urseptiya | Capsules 200 mg: from 10 to 200 pcs. |
Dosage Form, Packaging, and Composition
Capsules hard, gelatin, size #1, with a white body and a green cap; the capsule contents are a powder ranging from white with a yellowish tint to light yellow in color, and clumping of the powder is allowed.
| 1 caps. | |
| Pipemidic acid trihydrate | 236 mg, |
| Equivalent to pipemidic acid content | 200 mg |
Excipients: colloidal silicon dioxide (aerosil), magnesium stearate, sodium carboxymethyl starch (primogel, sodium starch glycolate), lactose monohydrate (milk sugar).
Gelatin capsule compositionCap composition: titanium dioxide, brilliant blue dye, quinoline yellow dye, gelatin.
Body composition titanium dioxide, gelatin.
From 10 to 20 pcs. – blister packs (from 1 to 10 pcs.) – cardboard packs.
From 10 to 200 pcs. – jars (1) – cardboard packs.
Clinical-Pharmacological Group
Antibacterial drug of the quinoline group
Pharmacotherapeutic Group
Systemic antibacterial agents; quinolone derivatives; other quinolones
Pharmacological Action
Uroantiseptic, a derivative of 4-quinolone. It has a bactericidal effect, due to the binding of divalent iron ions and the inhibition of the enzymatic systems of the microbial cell.
It is active against most gram-negative bacteria: Pseudomonas aeruginosa, Escherichia coli, Proteus spp., Klebsiella spp., Shigella spp., Salmonella spp.
It is also active against some gram-positive bacteria, in particular Staphylococcus aureus.
Pharmacokinetics
After oral administration, Cmax in blood plasma is reached in 2 hours. Bioavailability is 60%, binding to plasma proteins is 15%. T1/2 is 3 hours. 50-70% is excreted in the urine.
Indications
Infectious and inflammatory diseases caused by susceptible microorganisms (including pyelonephritis, urethritis, cystitis, prostatitis).
ICD codes
| ICD-10 code | Indication |
| N10 | Acute tubulointerstitial nephritis (acute pyelonephritis) |
| N11 | Chronic tubulointerstitial nephritis (chronic pyelonephritis) |
| N30 | Cystitis |
| N34 | Urethritis and urethral syndrome |
| N41 | Inflammatory diseases of prostate |
| ICD-11 code | Indication |
| GA91.Z | Inflammatory and other diseases of prostate, unspecified |
| GB50 | Acute tubulo-interstitial nephritis |
| GB51 | Acute pyelonephritis |
| GB55.Z | Chronic tubulo-interstitial nephritis, unspecified |
| GB5Z | Renal tubulo-interstitial diseases, unspecified |
| GC00.Z | Cystitis, unspecified |
| GC02.Z | Urethritis and urethral syndrome, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer orally with a full glass of water.
The standard adult dosage is 400 mg twice daily (equivalent to two 200 mg capsules per dose).
Maintain this regimen for a full treatment course of 10 days, even if symptoms improve earlier.
For more severe infections, a single dose may be increased to 600 mg (three 200 mg capsules) twice daily, based on physician assessment.
In cases of frequent acute urinary tract infections in women, administer the drug intravaginally concurrently with the oral regimen as directed.
Ensure adequate hydration during therapy; increase fluid intake under diuresis control.
Take the doses at approximately 12-hour intervals to maintain consistent plasma concentrations.
Do not exceed the prescribed daily dose or duration of treatment.
Adverse Reactions
From the digestive system nausea, vomiting, diarrhea.
Allergic reactions skin rash, itching.
Contraindications
Severe renal impairment (creatinine clearance <10 ml/min), severe hepatic impairment, first and third trimesters of pregnancy, childhood, hypersensitivity to pipemidic acid.
Use in Pregnancy and Lactation
Pipemidic acid is contraindicated for use in the first and third trimesters of pregnancy. Use in the second trimester of pregnancy and during lactation (breastfeeding) should be carried out with caution, only in cases where the expected therapeutic benefit for the mother outweighs the potential risk of side effects in the fetus or child.
Use in Hepatic Impairment
Contraindicated in severe hepatic impairment.
Use in Renal Impairment
Contraindicated in severe renal impairment (creatinine clearance <10 ml/min).
Pediatric Use
Contraindicated in childhood.
Special Precautions
During treatment, ultraviolet radiation should be avoided due to the high risk of photosensitivity; increase the amount of fluid consumed (under the control of diuresis).
Drug Interactions
With simultaneous use with drugs that alkalize urine, the activity of pipemidic acid is enhanced.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
OKI, sachets 80mg 2g, 12pcs
Mildronate capsules 500mg, 90pcs
Noopept, pills 10mg, 50pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Belosalic, ointment, 30g
Arbidol, capsules 100mg, 40pcs
Daivobet, ointment, 30g 